Innovative therapeutics

Investors/
Media

Welcome to BioMarin’s Investor Relations & Media Page

We’ve brought together a variety of information in one location to better assist you in your efforts to research and develop news articles and learn about our company.

BioMarin Pharmaceutical Inc. was founded in 1997, and since July 1999 the company's common stock has been traded on the Nasdaq National Market under the ticker symbol BMRN. BioMarin's policy is to fully comply with all rules put forth by the Securities and Exchange Commission and the Nasdaq National Market. For misplaced stock certificates, please contact our transfer agent directly.

Recent News
Aug 13, 2020

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) validated the Company's Marketing Authorization Application (MAA) for vosoritide, an...

Aug 10, 2020

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jeff Ajer, Executive Vice President and Chief Commercial Officer, and Brian Mueller, Executive Vice President, Chief Financial...

Aug 4, 2020

Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2020 2019 % Change 2020 2019 % Change Total Revenues $ 429.5

Events & Presentations
Thursday, August 13, 2020
1:00pm - 1:25pm EDT
Tuesday, August 11, 2020
10:55am - 11:25am EDT

Stock Quote
NASDAQBMRN
BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU

Products

Palynziq®
Brineura®
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information